Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Shasun Chemicals and Drugs Limited
Shasun Chemicals and Drugs Limited
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Finance
Strides Shasun acquires three OTC brands from Moberg Pharma
Indian firm is building an over-the-counter drug franchise in regulated and emerging markets
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Ingredients
Indian API market on the up as domestic drug prices fall
Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Ingredients
Indian pharma exports to be hit by Falsified Medicines Directive
API exporters say latest EU move is a non-issue
Subscribe now